RAYMOR INDUSTRIES INC.

RAYMOR INDUSTRIES INC.

March 23, 2005 09:00 ET

Raymor Received a Strategic Order from STRYKER Corporation for its Biomedical Titanium Powder


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: RAYMOR INDUSTRIES INC.

TSX VENTURE SYMBOL: RAR

MARCH 23, 2005 - 09:00 ET

Raymor Received a Strategic Order from STRYKER
Corporation for its Biomedical Titanium Powder

MONTREAL, QUEBEC--(CCNMatthews - March 23, 2005) - Raymor Industries
(TSX VENTURE:RAR) is proud to announce that its wholly-owned industrial
subsidiary, AP&C Advanced Powders & Coatings Inc. (AP&C) has concluded a
contract for Titanium powder production with STRYKER Corporation (NYSE:
SYK). STRYKER will use this unique powder, given its sphericity and its
purity, to create lasting biocompatible coatings for its new generation
of innovative orthopedic implants.

The ultra-spherical titanium powder allows STRYKER to produce high
quality orthopedic implants. Before issuing a purchase order to AP&C,
Stryker conducted a worldwide search to find a powder which would
provide optimal longevity and biocompatibility for its orthopedic
implants.

Thanks to AP&C's patented plasma atomization process, biomedical powders
are of a high purity, with an exceptional sphericity. The spherical
nature of the powder provides an evenly-distributed coating for
artificial joints, thus allowing for the optimization of the coating
porosity, which facilitates tissue growth.

"The STRYKER contract represents for AP&C a breakthrough in the
biomedical sector with a large US company. STRYKER is one of the three
global leaders in human orthopedic implants, and we are pleased to have
been selected by them," said Mr. Stephane Robert, President of Raymor
Industries.

"STRYKER received FDA (US Food & Drug Administration) approval for these
innovative orthopedic implants using AP&C powder, enabling us to begin a
long-term business relationship," adds Mr. Robert.

According to Dr. Michel Drouet, Chief Scientist with AP&C, "At the
beginning of the 90's, I began development work on this plasma
atomization process, which is unique in the world, at Hydro-Quebec's
Shawinigan laboratories, in collaboration with Noranda. Thanks to AP&C,
I am extremely happy to see all this research effort leading to
commercialization in the orthopedic implant sector with a client as
prestigious as STRYKER."

"With this Titanium powder, other applications will be commercialized,
including the metal injection molding of components for the aerospace
sector. With our Plasma Atomization Process, we can in fact consider
taking a foot-hold in other promising markets with other types of
nano-sized and micron-sized metallic powders," adds Dr. Drouet.

With other negotiations underway, AP&C foresees the installation of a
second reactor in its facility, which could hold up to six units. The
forecasted revenue from powder sales is in the order of $3.5 million per
year, per reactor.

The world market for orthopedic implants was more than US$6.4 billion in
2002. Analysts from the renowned Freedonia Group predict markets of
US$8.7 billion in 2007 and US$11.6 billion in 2012. The overall growth
rate for this sector will be 6.2%. However, Freedonia Group and Frost &
Sullivan both agree that this growth rate can increase significantly (up
to 15% per year), given the potential removal of certain
anti-inflammatory and pain medications from the market place by the FDA.
As well, an aging population will likely have an impact on the
orthopedic implant market growth rate.

RAYMOR INDUSTRIES INC. (TSX-V:RAR) has for mission to be the largest
Canadian developer of high technology and a producer/recycler of
advanced materials and nanomaterials for high value-added applications.
In November 2004, Raymor Industries created a wholly-owned, industrial
subsidiary, AP&C Advanced Powders and Coatings, specializing in
nanotechnology and advanced materials, and comprising four operational
divisions: (1) metal and ceramic coatings, which largely targets
aerospace, military, and mining applications; (2) spherical metallic
powders, primarily used for biomedical and aerospace applications; (3)
nanotechnology products, including nano-powders, nano-coatings, and
carbon nanotubes for "the applications of tomorrow"; and (4) net-shape
forming, a component manufacturing technique used for ballistic
protection and other aerospace and military applications. Raymor holds
the exclusive rights to 20 patents throughout the world.

ON BEHALF OF THE BOARD OF DIRECTORS

Stephane Robert, President.

FOR MORE INFORMATION ON NANOTECHNOLOGY AND ITS POTENTIAL, PLEASE VISIT
THE FOLLOWING SITE: www.nanoquebec.ca


-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    RAYMOR INDUSTRIES INC.
    Raymond Fournel
    Investor Relations
    (514) 932-3485 (NEW)
    (514) 932-3644 (NEW) (FAX)
    investor@raymor.com
    www.raymor.com
    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release